The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kjaergaard, J.
Right arrow Articles by Shu, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kjaergaard, J.
Right arrow Articles by Shu, S.
The Journal of Immunology, 1999, 163: 751-759.
Copyright © 1999 by The American Association of Immunologists

Tumor Infiltration by Adoptively Transferred T Cells Is Independent of Immunologic Specificity but Requires Down-Regulation of L-Selectin Expression1

Jørgen Kjaergaard and Suyu Shu2

Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, OH 44195

Adoptive immunotherapy with anti-CD3/IL-2 activated tumor-draining lymph node (LN) T cells is capable of eradicating tumor established at various histological sites. Tumor-specific effector lymphocytes have recently been identified to be LN T cells with down-regulated L-selectin (L-selectin-). Using fluorochrome labeling, the present study determined the early trafficking pattern of systemically transferred cells. In mice with 10-day established pulmonary 3-methylcholanthrene (MCA) 205 metastases, accumulation of cells in tumors was evident as early as 2 h after i.v. cell transfer, and, by 24 h, >50-fold higher numbers of cells were seen in metastases than in normal tissues. Similarly, transferred cells selectively infiltrated s.c. tumors, albeit at a lower rate. Analysis of the transferred cells isolated from recipient mice revealed that tumor-infiltrating cells were mostly L-selectin- (>95%). By contrast, only 24% and 58% L-selectin- cells were found in the LN and spleen, respectively. The ability of L-selectin- cells to accumulate at tumor sites was confirmed by the transfer of purified cell populations. Despite this selective tumor infiltration, the trafficking pattern did not reflect antigenetic specificity, and tumor regression occurred only after the transfer of tumor-specific effector cells. These results, thus, suggest that there are two distinct mechanisms operative in successful adoptive immunotherapy. Early infiltration of tumors by transferred cells is dictated by the physiological properties of cells and is independent on their immunologic specificity. Tumor regression, however, requires immunologically specific interactions at the site of tumor.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
K. Sasaki, X. Zhao, A. D. Pardee, R. Ueda, M. Fujita, S. Sehra, M. H. Kaplan, L. P. Kane, H. Okada, and W. J. Storkus
Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo
J. Immunol., July 1, 2008; 181(1): 104 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. J. Sussman, R. Parihar, K. Winstead, and F. D. Finkelman
Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion
Cancer Res., December 15, 2004; 64(24): 9124 - 9130.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
C. S. Chin, C. H.T. Miller, L. Graham, M. Parviz, S. Zacur, B. Patel, A. Duong, and H. D. Bear
Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes
Int. Immunol., September 1, 2004; 16(9): 1283 - 1294.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Skitzki, R. A. Craig, R. Okuyama, R. N. Knibbs, K. McDonagh, A. E. Chang, and L. M. Stoolman
Donor Cell Cycling, Trafficking, and Accumulation during Adoptive Immunotherapy for Murine Lung Metastases
Cancer Res., March 15, 2004; 64(6): 2183 - 2191.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Peng, J. Kjaergaard, G. E. Plautz, M. Awad, J. A. Drazba, S. Shu, and P. A. Cohen
Tumor-Induced L-Selectinhigh Suppressor T Cells Mediate Potent Effector T Cell Blockade and Cause Failure of Otherwise Curative Adoptive Immunotherapy
J. Immunol., November 1, 2002; 169(9): 4811 - 4821.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Huang, F. Li, J. R. Gordon, and J. Xiang
Synergistic Enhancement of Antitumor Immunity with Adoptively Transferred Tumor-specific CD4+ and CD8+ T Cells and Intratumoral Lymphotactin Transgene Expression
Cancer Res., April 1, 2002; 62(7): 2043 - 2051.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Ganss, E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling
Combination of T-Cell Therapy and Trigger of Inflammation Induces Remodeling of the Vasculature and Tumor Eradication
Cancer Res., March 1, 2002; 62(5): 1462 - 1470.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. N. Le, N. C. Lee, K. Tsung, and J. A. Norton
Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12
J. Immunol., December 15, 2001; 167(12): 6765 - 6772.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu
Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor
J. Immunol., December 1, 2001; 167(11): 6669 - 6677.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
T. M. Carlos
Leukocyte recruitment at sites of tumor: dissonant orchestration
J. Leukoc. Biol., August 1, 2001; 70(2): 171 - 184.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Ansell, M. Stenson, T. M. Habermann, D. F. Jelinek, and T. E. Witzig
CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin's Lymphoma Predicts Patient Outcome
J. Clin. Oncol., February 1, 2001; 19(3): 720 - 726.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Ahmadzadeh, S. F. Hussain, and D. L. Farber
Heterogeneity of the Memory CD4 T Cell Response: Persisting Effectors and Resting Memory T Cells
J. Immunol., January 15, 2001; 166(2): 926 - 935.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Peng, J. Kjaergaard, G. E. Plautz, D. E. Weng, S. Shu, and P. A. Cohen
Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression
J. Immunol., November 15, 2000; 165(10): 5738 - 5749.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. E. Plautz, S. Mukai, P. A. Cohen, and S. Shu
Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors
J. Immunol., October 1, 2000; 165(7): 3656 - 3662.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. E. Plautz, D. W. Miller, G. H. Barnett, G. H. J. Stevens, S. Maffett, J. Kim, P. A. Cohen, and S. Shu
T Cell Adoptive Immunotherapy of Newly Diagnosed Gliomas
Clin. Cancer Res., June 1, 2000; 6(6): 2209 - 2218.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. Mukai, J. Kjargaard, S. Shu, and G. E. Plautz
Infiltration of Tumors by Systemically Transferred Tumor-Reactive T Lymphocytes Is Required for Antitumor Efficacy
Cancer Res., October 1, 1999; 59(20): 5245 - 5249.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.